Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

242.64 -7.35 (-2.94%)

Streaming Delayed Price Updated: 11:27 AM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know ↗

February 16, 2024

Via Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday? ↗

February 15, 2024

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

Via Benzinga

Why Alnylam Pharmaceuticals Stock Is Sinking Today ↗

February 15, 2024

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

Via The Motley Fool

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Alnylam Pharmaceuticals's Earnings Outlook ↗

February 14, 2024

Via Benzinga

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

February 06, 2024

Via Benzinga

Analyst Expectations for Alnylam Pharmaceuticals's Future ↗

December 08, 2023

Via Benzinga

Expert Ratings for Alnylam Pharmaceuticals ↗

November 15, 2023

Via Benzinga

Earnings Outlook For Alnylam Pharmaceuticals ↗

November 01, 2023

Via Benzinga

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again ↗

January 12, 2024

There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.

Via Investor's Business Daily

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗

January 04, 2024

A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗

December 29, 2023

Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.

Via Benzinga

Expert Ratings for Alnylam Pharmaceuticals ↗

October 16, 2023

Via Benzinga

Analyst Expectations for Alnylam Pharmaceuticals's Future ↗

September 29, 2023

Via Benzinga

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

Why Newly Listed Korro Bio Shares Are Gaining Today ↗

December 04, 2023

H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.

Via Benzinga

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

October 11, 2023

Via Benzinga

CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗

October 11, 2023

Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 ↗

October 11, 2023

Via Benzinga

Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today? ↗

October 09, 2023

The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin-

Via Benzinga

Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug ↗

October 09, 2023

Shares skidded to their lowest point since September on the FDA's rejection.

Via Investor's Business Daily

2 Growth Stocks That Could Rocket Higher Before the End of 2023 ↗

October 08, 2023

Potential approvals of new medicines expected soon could push these stocks through the roof.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

October 05, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects ↗

September 14, 2023

On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.

Via Benzinga

Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer ↗

September 14, 2023

Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.